Valuation: Sinotherapeutics Inc.

Market Cap 3.8B 560M 490M 451M 418M 793M 53.42B 806M 5.41B 2.12B 26.23B 2.1B 2.06B 90.86B P/E 2024
35.9x
P/E 2025 88.2x
Enterprise Value 3.06B 450M 393M 363M 336M 637M 42.93B 648M 4.35B 1.7B 21.08B 1.69B 1.65B 73.03B EV / Sales 2024
7.4x
EV / Sales 2025 8.08x
Free-Float
24.34%
Yield 2024
0.62%
Yield 2025 0.36%
1 day-1.51%
1 week-11.03%
Current month+12.63%
1 month+6.94%
3 months-10.84%
6 months-17.69%
Current year-12.68%
1 week 8.12
Extreme 8.12
9.64
1 month 7.02
Extreme 7.02
9.88
Current year 7.02
Extreme 7.02
10.89
1 year 7.02
Extreme 7.02
13.28
3 years 6.3
Extreme 6.3
14.55
5 years 6.3
Extreme 6.3
28
10 years 6.3
Extreme 6.3
28
Manager TitleAgeSince
Chief Executive Officer 53 2023-04-05
Director of Finance/CFO 57 2025-04-29
Investor Relations Contact 44 2023-05-30
Director TitleAgeSince
Chairman 53 2020-08-17
Director/Board Member 58 2012-07-31
Director/Board Member 44 2018-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.51%-11.03%-20.92%-32.51% 560M
-0.17%+1.61%+16.42%+85.22% 48.73B
+1.04%-1.02%+69.47%+115.88% 35.82B
-0.13%-1.29%-2.60%+41.58% 12.2B
-0.71%+0.89%+18.28%+97.87% 12.11B
+0.76%+1.75%+34.02%+123.93% 9.11B
-0.86%+0.37%+52.61%-3.54% 7.09B
+1.00%-0.57%+17.78%+45.15% 7B
+0.69%+3.25%+19.90%+243.91% 6.7B
-2.19%-3.38%-22.26%+7.68% 5.78B
Average -0.21%-1.26%+18.27%+72.52% 14.51B
Weighted average by Cap. +0.12%+0.25%+29.49%+90.13%

Financials

2024 2025
Net sales 512M 75.29M 65.86M 60.73M 56.19M 107M 7.19B 108M 727M 285M 3.53B 283M 277M 12.22B 447M 65.71M 57.49M 53.01M 49.05M 93.1M 6.27B 94.65M 635M 249M 3.08B 247M 241M 10.67B
Net income 128M 18.79M 16.44M 15.16M 14.03M 26.62M 1.79B 27.07M 182M 71.16M 881M 70.54M 69.02M 3.05B 47.48M 6.99M 6.11M 5.64M 5.22M 9.9M 667M 10.06M 67.5M 26.46M 328M 26.23M 25.66M 1.13B
Net Debt -734M -108M -94.43M -87.08M -80.57M -153M -10.3B -155M -1.04B -409M -5.06B -405M -396M -17.53B -746M -110M -96.09M -88.61M -81.98M -156M -10.48B -158M -1.06B -416M -5.15B -412M -403M -17.83B
Logo Sinotherapeutics Inc.
Sinotherapeutics Inc is a China-based company mainly engaged in the research and development, product registration, production and sales of generic drugs, as well as contract research organization/contract manufacture organization (CRO/CMO) services. The Company's main products include posaconazole enteric-coated tablets, mesalazine enteric-coated tablets, ursodeoxycholic acid capsules and others. The Company's products cover multiple fields including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, nephrology, and analgesia. The Company's CRO/CMO services are primarily formulation CRO/CMO services, providing pharmaceutical companies and research institutions with specialized formulation development services during drug development and commercial manufacturing services after drug approval through contracts. The Company mainly conducts its business in the domestic and overseas markets.
Employees
319
Date Price Change Volume
26-07-09 CN¥8.470 -1.51% 7,704,025
26-07-08 CN¥8.600 -4.76% 7,409,460
26-07-07 CN¥9.030 -2.17% 7,717,199
26-07-06 CN¥9.230 -1.91% 12,213,279
26-07-03 CN¥9.410 -1.16% 13,663,647
  1. Stock Market
  2. Stocks
  3. 688247 Stock